CZ303929B6 - Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie - Google Patents

Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie Download PDF

Info

Publication number
CZ303929B6
CZ303929B6 CZ20023166A CZ20023166A CZ303929B6 CZ 303929 B6 CZ303929 B6 CZ 303929B6 CZ 20023166 A CZ20023166 A CZ 20023166A CZ 20023166 A CZ20023166 A CZ 20023166A CZ 303929 B6 CZ303929 B6 CZ 303929B6
Authority
CZ
Czechia
Prior art keywords
factor viii
ser
leu
vector
glu
Prior art date
Application number
CZ20023166A
Other languages
Czech (cs)
English (en)
Other versions
CZ20023166A3 (cs
Inventor
Hauser@Charlotte
Hörster@Andrea
Schröder@Carola
Lehnerer@Michael
Original Assignee
Octapharma Biopharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/en
Application filed by Octapharma Biopharmaceuticals Gmbh filed Critical Octapharma Biopharmaceuticals Gmbh
Publication of CZ20023166A3 publication Critical patent/CZ20023166A3/cs
Publication of CZ303929B6 publication Critical patent/CZ303929B6/cs

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/6437Coagulation factor VIIa (3.4.21.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/644Coagulation factor IXa (3.4.21.22)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424Serine endopeptidases (3.4.21)
    • C12N9/647Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21021Coagulation factor VIIa (3.4.21.21)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21022Coagulation factor IXa (3.4.21.22)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
CZ20023166A 2000-03-22 2001-03-21 Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie CZ303929B6 (cs)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (en) 2000-03-22 2000-03-22 Production of recombinant blood clotting factors in human cell lines
US20324900P 2000-05-08 2000-05-08

Publications (2)

Publication Number Publication Date
CZ20023166A3 CZ20023166A3 (cs) 2003-02-12
CZ303929B6 true CZ303929B6 (cs) 2013-07-03

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
CZ20023166A CZ303929B6 (cs) 2000-03-22 2001-03-21 Mutein faktoru VIII, odpovídající DNA sekvence, vektor a hostitelská bunka, farmaceutická kompozice, zpusob produkce muteinu a imortalizovaná lidská bunecná linie

Country Status (28)

Country Link
US (1) US7572619B2 (enExample)
EP (2) EP1460131A3 (enExample)
JP (1) JP3894795B2 (enExample)
KR (1) KR100581574B1 (enExample)
CN (1) CN1454257B (enExample)
AT (1) ATE312176T1 (enExample)
AU (3) AU2001254715B2 (enExample)
BE (1) BE2014C077I2 (enExample)
BG (1) BG65930B1 (enExample)
BR (1) BRPI0109494B8 (enExample)
CA (1) CA2404163C (enExample)
CZ (1) CZ303929B6 (enExample)
DE (1) DE60115613T2 (enExample)
DK (1) DK1266006T3 (enExample)
EA (1) EA004317B1 (enExample)
EE (1) EE200200538A (enExample)
ES (1) ES2254403T3 (enExample)
FR (1) FR15C0003I2 (enExample)
HR (1) HRP20020767B1 (enExample)
HU (1) HU228091B1 (enExample)
IL (2) IL151857A0 (enExample)
MX (1) MXPA02009221A (enExample)
NO (1) NO330910B1 (enExample)
NZ (1) NZ521732A (enExample)
RS (1) RS50743B (enExample)
SI (1) SI1266006T1 (enExample)
SK (1) SK287706B6 (enExample)
WO (1) WO2001070968A2 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0109494B8 (pt) * 2000-03-22 2021-05-25 Octagene Gmbh muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
MXPA03002256A (es) * 2000-09-19 2003-09-10 Univ Emory Factor viii modificado.
EP1469064A1 (en) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression of proteins in endothelial cells derived from precursor cells from cord blood
ATE489105T1 (de) 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
DK2438931T3 (da) 2004-09-22 2013-12-02 St Jude Childrens Res Hospital Forbedret ekspression af faktor ix i genterapivektorer
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
CN101120085B (zh) * 2005-02-11 2011-06-08 诺和诺德医疗保健公司 在包含植物蛋白水解产物的无血清细胞培养液中生产多肽
EP1707634A1 (en) 2005-03-29 2006-10-04 Octapharma AG Method for isolation of recombinantly produced proteins
EP1739179A1 (en) 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
DK2041270T3 (da) 2006-07-13 2014-01-27 Wyeth Llc Fremstilling af glycoproteiner
WO2008134665A1 (en) * 2007-04-26 2008-11-06 Inspiration Biopharmaceuticals, Inc. Recombinant vitamin k dependent proteins with high sialic acid content and methods of preparing same
EP2198870A4 (en) * 2007-08-27 2011-08-03 Univ Nagoya Nat Univ Corp ACTIVATOR FOR BLOOD CREATION FACTOR VII PROMOTER AND ITS USE
RU2011110459A (ru) 2008-08-21 2012-09-27 Октафарма АГ (CH) Рекомбинантно полученный человеческий фактор viii и ix
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
PT2482841T (pt) 2009-10-02 2019-03-01 Childrens Hospital Philadelphia A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
RU2607374C2 (ru) 2009-10-30 2017-01-10 Новозаймс Байофарма Дк А/С Варианты альбумина
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
EP2679681B2 (en) 2011-02-25 2023-11-15 Chugai Seiyaku Kabushiki Kaisha FcgammaRIIB-specific FC antibody
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
AU2012257736B2 (en) 2011-05-13 2015-12-10 Octapharma Ag A method of increasing the productivity of eucaryotic cells in the production of recombinant FVIII
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素-n-硫酸酯酶之方法
EP4011913A1 (en) 2011-06-30 2022-06-15 Chugai Seiyaku Kabushiki Kaisha Heterodimerized polypeptide
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
WO2013057219A1 (en) 2011-10-18 2013-04-25 Csl Behring Gmbh Method for improving the stability of purified factor viii after reconstitution
US20140315817A1 (en) 2011-11-18 2014-10-23 Eleven Biotherapeutics, Inc. Variant serum albumin with improved half-life and other properties
CN104080909A (zh) 2011-11-30 2014-10-01 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
MX2014010278A (es) 2012-03-16 2015-03-05 Novozymes Biopharma Dk As Variantes de albumina.
JP6254146B2 (ja) 2012-03-27 2017-12-27 エヌジーエム バイオファーマシューティカルス,インコーポレーテッド 代謝障害を治療するための組成物および方法
GB201210357D0 (en) * 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
WO2014008172A2 (en) * 2012-07-03 2014-01-09 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
EP3404105A1 (en) 2012-07-06 2018-11-21 Bioverativ Therapeutics Inc. Cell line expressing single chain factor viii polypeptides and uses thereof
CN105452290A (zh) 2012-11-08 2016-03-30 诺维信生物制药丹麦公司 白蛋白变体
CN105025920A (zh) * 2013-01-24 2015-11-04 博尔托拉制药公司 具有因子Xa衍生物的组织因子途径抑制剂的抑制
CA2908350C (en) 2013-04-02 2023-08-08 Futa Mimoto Fc region variant
EP2853538A1 (en) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues of temporin-SHa and uses thereof
SG10201802098UA (en) * 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN115043945A (zh) 2014-10-31 2022-09-13 Ngm生物制药有限公司 用于治疗代谢病症的组合物和方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
MY181199A (en) 2014-12-19 2020-12-21 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
WO2016198499A1 (en) 2015-06-09 2016-12-15 Glycotope Gmbh IMPROVED METHOD FOR PRODUCTION OF γ-CARBOXYLATED POLYPEPTIDES
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Il−8関連疾患の治療用又は予防用組成物
WO2018210771A1 (en) 2017-05-17 2018-11-22 Octapharma Ag Method for the production of a recombinant target protein
EP3710589A4 (en) 2017-11-14 2021-11-10 Chugai Seiyaku Kabushiki Kaisha ANTI-C1S ANTIBODIES AND METHOD OF USING
WO2020020364A1 (zh) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 一种制备重组人凝血因子ⅷ的方法
SG10202106830VA (en) 2018-08-10 2021-08-30 Chugai Pharmaceutical Co Ltd Anti-cd137 antigen-binding molecule and utilization thereof
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
AU2019366942B2 (en) 2018-10-23 2025-10-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor VIII function
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
CA3221235A1 (en) 2021-06-11 2022-12-15 Ali Ladram Short antimicrobial peptides

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009122A1 (en) * 1989-12-15 1991-06-27 Kabivitrum Ab A recombinant human factor viii derivative
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
EP1266006A2 (en) * 2000-03-22 2002-12-18 Octagene GmbH Production of recombinant muteins of blood clotting factor viii in human cell lines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI86885C (fi) * 1984-04-20 1992-10-26 Genentech Inc Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
AU5864086A (en) * 1985-04-22 1986-11-18 Genetics Institute Inc. High yield production of active factor ix
DE3785102T2 (de) * 1986-01-03 1993-07-22 Genetics Inst Verfahren zur herstellung von faktor-viii:c-typ-proteinen.
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5024939A (en) * 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
CA2135744A1 (en) * 1989-11-17 1991-05-18 Barbara Chapman Protein complexes having factor viii:c activity and production thereof
FI923347A0 (fi) * 1990-01-26 1992-07-23 Immuno Ag Blodfaktorer producerade med rekombinant-dna-teknik och foerfarande foer expression av naemnda blodfaktorer samt i naemnda foerfarande anvaenda rekombinanta kokoppvirus.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
EP0951544A2 (en) * 1996-07-03 1999-10-27 Chiron Corporation Methods for administration of recombinant gene delivery vehicles for treatment of human disease
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
JP2002537311A (ja) 1999-02-19 2002-11-05 オクタジーン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング ホルモン−ホルモン受容体の複合体および核酸構築物、並びに遺伝子治療におけるそれらの使用
WO2001012836A1 (en) * 1999-08-13 2001-02-22 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2 domain in the presence or absence of a bound ligand and methods of use thereof
WO2003009237A1 (en) * 2001-07-18 2003-01-30 Skaginn Hf. A method and apparatus for relating information of a processed object to an operator

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991009122A1 (en) * 1989-12-15 1991-06-27 Kabivitrum Ab A recombinant human factor viii derivative
WO1994029471A1 (en) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Adenoviral vectors for treatment of hemophilia
WO1999029848A1 (en) * 1997-12-05 1999-06-17 The Immune Response Corporation Novel vectors and genes exhibiting increased expression
EP1266006A2 (en) * 2000-03-22 2002-12-18 Octagene GmbH Production of recombinant muteins of blood clotting factor viii in human cell lines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lind a kol. (1995) Eur. J. Biochem. 232, 19-27, viz Obr. 2, str. 22 *

Also Published As

Publication number Publication date
FR15C0003I1 (fr) 2015-02-27
BG107152A (bg) 2003-06-30
SK287706B6 (en) 2011-07-06
JP3894795B2 (ja) 2007-03-22
WO2001070968A3 (en) 2001-12-13
EA200201008A1 (ru) 2003-02-27
IL151857A (en) 2010-05-31
WO2001070968A2 (en) 2001-09-27
BRPI0109494B8 (pt) 2021-05-25
DE60115613D1 (de) 2006-01-12
KR20030011079A (ko) 2003-02-06
EE200200538A (et) 2004-04-15
DE60115613T2 (de) 2006-08-24
HUP0300588A2 (hu) 2003-06-28
HRP20020767A2 (en) 2005-02-28
EP1460131A3 (en) 2005-06-01
DK1266006T3 (da) 2006-01-16
US20040023333A1 (en) 2004-02-05
CA2404163C (en) 2009-09-29
AU5471501A (en) 2001-10-03
BE2014C077I2 (enExample) 2020-01-30
ES2254403T3 (es) 2006-06-16
HUP0300588A3 (en) 2005-09-28
AU2006201848A1 (en) 2006-05-25
YU71002A (sh) 2005-11-28
AU2001254715B2 (en) 2006-02-02
EA004317B1 (ru) 2004-02-26
SK15042002A3 (sk) 2003-09-11
FR15C0003I2 (fr) 2015-11-20
JP2003530093A (ja) 2003-10-14
BRPI0109494B1 (pt) 2021-05-11
NO20024475L (no) 2002-11-20
NO330910B1 (no) 2011-08-15
IL151857A0 (en) 2003-04-10
BR0109494A (pt) 2002-12-10
EP1266006B1 (en) 2005-12-07
SI1266006T1 (sl) 2006-06-30
NZ521732A (en) 2004-05-28
RS50743B (sr) 2010-08-31
CN1454257B (zh) 2013-01-16
MXPA02009221A (es) 2005-07-25
EP1266006A2 (en) 2002-12-18
CN1454257A (zh) 2003-11-05
BG65930B1 (bg) 2010-05-31
HU228091B1 (en) 2012-10-29
CZ20023166A3 (cs) 2003-02-12
NO20024475D0 (no) 2002-09-19
ATE312176T1 (de) 2005-12-15
KR100581574B1 (ko) 2006-05-22
US7572619B2 (en) 2009-08-11
CA2404163A1 (en) 2001-09-27
HRP20020767B1 (hr) 2011-09-30
EP1460131A2 (en) 2004-09-22

Similar Documents

Publication Publication Date Title
CA2404163C (en) Production of recombinant blood clotting factors in human cell lines
JP6909203B2 (ja) 第ix因子融合タンパク質及びそれらの製造方法及び使用方法
JP2888518B2 (ja) 改良型の組換え発現
AU2001254715A1 (en) Production of recombinant blood clotting factors in human cell lines
CN112912112B (zh) 肝特异性核酸调节元件以及其方法及用途
AU2016337408A1 (en) Inducible modification of a cell genome
PT1863920E (pt) Método para isolamento melhorado de proteínas recombinantemente produzidas
JPH0640942A (ja) 機能的な第viii因子の製造方法
CA2407881A1 (en) Vectors for ocular transduction and use thereof for genetic therapy
CN111733174B (zh) 一种分离的核酸分子及其用途
KR101921698B1 (ko) 재조합에 의해 제조된 인간 인자 ⅷ 및 ⅸ
TW202317753A (zh) 經武裝之嵌合受體及其使用方法
CN113260704B (zh) CYP4V2和RdCVF在制备药物中的用途
PL207713B1 (pl) Muteina czynnika VIII, kodująca ją sekwencja DNA, wektor obejmujący sekwencję DNA, komórka gospodarza stransformowana tym wektorem, sposób wytwarzania muteiny czynnika VIII, kompozycja farmaceutyczna, zastosowanie muteiny czynnika VIII lub wektora i linia unieśmiertelnionych komórek ludzkich
JP3422963B2 (ja) ペプチドおよびその用途
CN106834349B (zh) 一种安全性提高的病毒基因递送系统
AU2019273200B2 (en) Novel vector and use thereof
TW201307382A (zh) 因子vii/viia之量產方法
WO2009038475A1 (en) Systems for expression of heterologous proteins in m. capsulatus

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20210321